JMP Securities Remains a Hold on Turning Point Therapeutics (TPTX)
TipRanksAug 10, 2022 00:45 ET
SVB Securities Maintains a Hold Rating on Turning Point Therapeutics (TPTX)
TipRanksJul 31, 2022 23:35 ET
Turning Point analyst ratings
Benzinga Analyst RatingsJun 13, 2022 14:41 ET
Guggenheim Downgrades Turning Point Therapeutics to Neutral From Buy, Adjusts Price Target to $76 From $72
MT NewswiresJun 13, 2022 12:08 ET
SVB Securities Downgrades Turning Point Therapeutics to Market Perform From Outperform, Adjusts Price Target to $76 From $101
MT NewswiresJun 13, 2022 08:44 ET
Turning Point Thera Cut to Market Perform From Outperform by SVB Leerink
Dow JonesJun 13, 2022 08:18 ET
Turning Point Thera Price Target Cut to $76.00/Share From $101.00 by SVB Leerink
Dow JonesJun 13, 2022 08:18 ET
SVB Leerink Downgrades Turning Point to Market Perform, Lowers Price Target to $76
Benzinga Real-time NewsJun 13, 2022 08:08 ET
Analyst Ratings for Turning Point
Benzinga Real-time NewsJun 6, 2022 09:15 ET
Turning Point Thera Cut to Market Perform From Outperform by Cowen & Co.
Dow JonesJun 6, 2022 06:49 ET
Turning Point Thera Cut to Neutral From Buy by HC Wainwright & Co.
Dow JonesJun 6, 2022 06:32 ET
Turning Point Thera Price Target Cut to $76.00/Share From $161.00 by HC Wainwright & Co.
Dow JonesJun 6, 2022 06:32 ET
Wells Fargo Downgrades Turning Point Therapeutics to Equalweight From Overweight, Adjusts Price Target to $76 From $85
MT NewswiresJun 6, 2022 06:30 ET
Turning Point analyst ratings
Benzinga Analyst RatingsJun 6, 2022 06:22 ET
HC Wainwright & Co. Downgrades Turning Point to Neutral, Lowers Price Target to $76
Benzinga Real-time NewsJun 6, 2022 06:22 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicycle Therapeutics (BCYC), Turning Point Therapeutics (TPTX) and Globus Medical (GMED)
TipRanksJun 6, 2022 00:49 ET
Bristol Myers downgraded at Raymond James after Turning Point acquisition
Seeking AlphaJun 3, 2022 12:32 ET
Turning Point Thera Price Target Raised to $76.00/Share From $61.00 by Wedbush
Dow JonesJun 3, 2022 10:14 ET
Turning Point Thera Cut to Neutral From Outperform by Wedbush
Dow JonesJun 3, 2022 10:14 ET
Turning Point analyst ratings
Benzinga Analyst RatingsJun 3, 2022 10:04 ET
No Data
No Data